Lilly’s New Weight Loss Pill Drops (No Fasting Required!), Noom Buys Into the Peptide Wild West, and CVS Lets an AI Agent Take the Wheel

Hey all, 

Happy Friday! Noom’s pivot from calorie counting to the "longevity" market via experimental peptides proves that the consumerization of healthcare is about becoming a lifestyle brand. While it’s great that patients can now access "optimization" tools with the click of a button, are we really ready for a wild-west retail model where the line between medicine and a "gray market" subscription is getting dangerously blurry. It’s a brave new world where your health journey is managed by a marketing funnel and unproven chemicals, leaving us to wonder if we’re actually getting better care or just a much better checkout experience.

Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroRX)

[CNN] Lilly’s Foundayo FDA Approval and the Expansion of Oral GLP-1s

The FDA has approved Eli Lilly’s Foundayo (orforglipron), the second oral GLP-1 medication for weight loss, which distinguishes itself by offering flexible dosing without the strict fasting requirements of its competitors. Clinical trials demonstrated an average weight loss of 12% over 72 weeks, and the drug is positioned to improve accessibility through a fast-tracked approval process and significantly lower out-of-pocket pricing tiers. Science has officially peaked now that we can pursue our weight loss goals without the crushing emotional trauma of being told we have to wait thirty minutes to enjoy our first cup of morning coffee.

Full Article

(Endpoints News) Noom’s Strategic Expansion into Peptides

Weight loss startup Noom is pivoting toward the broader "longevity" market by acquiring Tailor Made Compounding, a move intended to offer various peptide-based therapies beyond standard GLP-1 drugs. While the company aims to provide regulated treatments for muscle repair and skin health once FDA restrictions are eased, many of these substances currently reside in a legal "gray market" with limited clinical evidence regarding their safety or efficacy. Apparently, nothing says "sustainable long-term growth" quite like building a business model around injecting customers with chemicals that the FDA currently considers a safety risk and a legal no-no.

Full Article

[Healthcare Brew] CVS Introduces Agentic AI Platform and Health100 Subsidiary

CVS Health has partnered with Google Cloud to launch an agentic AI platform under its new Health100 subsidiary, designed to unify patient data across its pharmacy, insurance, and clinical businesses. The system aims to increase consumer engagement by providing personalized, proactive health guidance throughout a patient's medical journey, such as coordinating care and supplies following a surgery. It's a real toss-up whether I’d rather be gaslit by a hallucinating agent or a hallucinating pharmacy tech named Trent.

Full Article